<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38693">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02155322</url>
  </required_header>
  <id_info>
    <org_study_id>4031-400</org_study_id>
    <nct_id>NCT02155322</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)</brief_title>
  <official_title>A Phase II Study of Pegylated Interferon Alfa-2b in AJCC Stage III (TxN1-2M0) Melanoma Subjects After Regional Lymph Node Dissection in Russia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant
      treatment for melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants who experience an adverse event (AE)</measure>
    <time_frame>Up to 13 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinue study medication due to an AE</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Pegylated Interferon Alfa-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon Alfa-2b</intervention_name>
    <description>6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks</description>
    <arm_group_label>Pegylated Interferon Alfa-2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon Alfa-2b</intervention_name>
    <description>3 μg/kg, weekly dosing, subcutaneous administration, Maintenance Phase - Up to 12 months after the 1st dose of PEG-IFN at 6 μg/kg</description>
    <arm_group_label>Pegylated Interferon Alfa-2b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Competent to self-administer the subcutaneous injections of PEG-IFN

          -  Histologically documented involved regional lymph nodes of a primary cutaneous
             melanoma or unknown primary, meeting the study's staging criteria

          -  Had the primary melanoma completely resected with adequate surgical margins and
             undergone operation for positive regional lymph nodes within 84 days of study start

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1

          -  Adequate hepatic, renal and bone marrow function as defined by study parameters
             obtained within 4 weeks prior to study start

          -  For a female subject who is of childbearing potential or male participant with female
             sexual partner who is of childbearing potential, agree to use acceptable methods of
             contraception for at least 2 weeks prior to study start and continue until at least 6
             months after last dose of study medication, or longer if dictated by local
             regulations

        Exclusion Criteria:

          -  Mucous membrane melanoma or ocular melanoma

          -  Known hypersensitivity to the components of study drug (including acetaminophen), or
             its analogs

          -  Evidence of distant or non-regional lymph node metastases or in-transit metastases

          -  Disease that cannot be completely surgically resected

          -  Prior malignancy within the past 5 years other than surgically cured non-melanoma
             skin cancer or cervical carcinoma in situ

          -  Severe cardiovascular disease, i.e. arrhythmias, requiring chronic treatment,
             congestive heart failure or symptomatic ischemic heart disease

          -  Hepatic decompensation

          -  Thyroid dysfunction not responsive to therapy

          -  Uncontrolled diabetes mellitus

          -  Clinically active autoimmune disease

          -  Clinically active and/or uncontrolled infection, including active hepatitis

          -  Human immunodeficiency virus (HIV)

          -  History of neuropsychiatric disorder requiring hospitalization

          -  Actively abusing alcohol or drugs

          -  Pregnant, lactating, or of reproductive potential and not using an effective means of
             contraception

          -  Medical condition requiring chronic systemic corticosteroids

          -  Received any experimental therapy within 30 days prior to enrolling in this study

          -  Received any prior chemotherapy, immunotherapy, hormonal or radiation therapy for
             melanoma

          -  Previously received interferon-α for any reason

          -  Known serious hypersensitivity reaction to PEG-IFN or interferon alfa-2b
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>June 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon Alfa-2a</mesh_term>
    <mesh_term>Interferon Alfa-2b</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Reaferon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
